PHD3 expression and contribution to malignancy have been detected in several cancers, including pancreatic biliary tumors [46], gastric cancer [47], NSCLC [48], breast cancer [49], and renal cell carcinoma (RCC) [50]. Here, EGLN3 is linked to renal cell carcinoma.